替吉奥联合康艾注射液治疗晚期非小细胞肺癌效果与预后因素分析.docVIP

替吉奥联合康艾注射液治疗晚期非小细胞肺癌效果与预后因素分析 　　[摘要] 目的 探讨替吉奥联合康艾注射液治疗晚期非小细胞肺癌（NSCLC）的效果、安全性及预后因素分析。 方法 选取2009年1月～2015年8月河北港口集团有限公司港口医院晚期NSCLC患者67例，替吉奥80 mg/（m2?d），分两次口服，联合康艾注射液60 mL/d，静滴，d1～14，21 d为1个周期。 结果 患者的客观缓解率（ORR）和疾病控制率（DCR）分别为10.4%和40.3%，单因素分析结果显示，不同的临床分级、病理分型、既往化疗方案数及本次化疗周期数所获得的DCR比较，差异均有统计学意义（P 0.05或P 0.01）。药物毒副作用绝大多数为Ⅰ～Ⅱ度，Ⅲ度毒副作用仅见于贫血（1/67），未观察到Ⅳ度毒副作用。患者的中位总生存和中位无进展生存分别为10.0个月和4.2个月；Cox多因素分析结果显示，年龄、病理类型、既往化疗方案数和本次化疗周期数为总生存的独立影响因素（P 0.05或P 0.01）。 结论 替吉奥联合康艾注射液治疗晚期非小细胞肺癌效果可靠、安全性好，且年龄、病理类型、既往化疗方案数和本次化疗的周期数为总生存的独立影响因素。 　　[关键词] 替吉奥；康艾注射液；晚期非小细胞肺癌；疗效；预后因素 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1673-7210（2016）10（b）-0083-04 　　[Abstract] Objective To investigate the efficacy and prognostic factors of S-1 combined with Kangai Injection in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods Sixty-seven patients with advanced NSCLC from January 2009 to August 2015 in Port Hospital of Hebei Port Group CO.，LTD， received oral S-1 80 mg/（m2?d） in two take orally daily and Kangai Injection （60 mL/d） intravenous dropping， on d1-14， repeated every 21 days. Results The ORR and DCR of the patients were 10.4% and 40.3% respectively. The DCR of different clinical classification， pathological type， number of previous chemotherapy regimens， and the chemotherapy cycles were statistically significant （P 0.05 or P 0.01）. The adverse reactions were generally Ⅰ-Ⅱ， Ⅲ degree adverse reactions occurred only in anemia （1/67）， and Ⅳ degree adverse reactions were not observed. The median OS and PFS of the patients were 10.0 months and 4.2 months， respectively. Cox proportional hazards regression model showed that， the age， pathological type， number of previous chemotherapy regimens and cycles of chemotherapy were independent prognostic factors of overall survival （P 0.05 or P 0.01）. Conclusion S-1 combined with Kangai Injection in treatment of NSCLC has reliable efficacy and safety. Age， pathological type， number of previous chemotherapy regimens and cycles of chemotherapy are ind